What Is Semaglutide and How Does It Work for Weight Loss?

Quick Answer

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that has become one of the most significant weight-loss medications on the market. It works by mimicking a natural gut hormone that regulates appetite, slows gastric emptying, and influences blood sugar control.

As of 2026, semaglutide is available in injectable form under the brand name Wegovy for weight management and as an oral tablet, with the pill version receiving FDA approval in December 2025 for chronic weight management.

Key Facts

• Semaglutide received FDA approval in January 2025 for reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
• The oral form of semaglutide was approved by the FDA in December 2025 for weight management, making it the first GLP-1 pill for this purpose.
• The oral tablet is expected to launch in the United States in early January 2026, with a starting dose of 1.5 mg.
• Wegovy, the injectable form approved for weight loss, received FDA approval in March 2024 for cardiovascular risk reduction in adults with known heart disease and overweight or obesity.
• In the STEP UP trial, semaglutide 7.2 mg achieved a 20.7% average weight reduction, outperforming the 2.4 mg dose and placebo.
• The SOUL trial demonstrated that oral semaglutide reduced major adverse cardiovascular events by 14% in high-risk type 2 diabetes patients.
• Semaglutide 2.4 mg improved liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to a Phase 3 trial published in the New England Journal of Medicine.
• Novo Nordisk lowered the cost of Ozempic to $499 per month for self-paying patients in August 2025.
• The FDA has issued warnings about counterfeit semaglutide injections circulating in the United States.
• Semaglutide is now available in multiple doses, including 1.5 mg, 4 mg, 9 mg, and 25 mg tablet formulations.

The Science Behind Semaglutide How a Diabetes Drug Became a Weight-Loss Powerhouse

Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. To understand how it works for weight loss, it helps to understand the biological system it targets.

GLP-1 is a naturally occurring incretin hormone released from the intestines after eating. Its primary jobs are to stimulate insulin secretion in response to food, suppress glucagon release, and signal to the brain that the body has received fuel.

The critical insight that made semaglutide revolutionary is that GLP-1 receptors are not only found in the pancreas—they are also densely located in brain regions that regulate appetite and reward. When semaglutide activates these receptors, it produces a cascade of effects that collectively reduce food intake.

Appetite Regulation and Satiety Signaling

One of the primary mechanisms of semaglutide is its effect on the hypothalamus, the brain region responsible for hunger and satiety. When the medication binds to GLP-1 receptors in this area, it increases feelings of fullness and reduces hunger signals.

Patients typically report that they feel satisfied with smaller portions and experience fewer food cravings. This is not a psychological effect—it is a direct pharmacological action on neural circuits.

The medication also affects the reward centers of the brain, particularly the mesolimbic dopamine pathway. This system is involved in the pleasurable aspects of eating, especially highly palatable, calorie-dense foods.

By modulating this circuitry, semaglutide appears to reduce the "food noise"—the constant intrusive thoughts about eating that many people with obesity experience.

Slowed Gastric Emptying

Semaglutide also slows the rate at which food leaves the stomach and enters the small intestine. This delayed gastric emptying means that meals remain in the stomach longer, which physically extends the period of satiety after eating.

It also flattens post-meal blood sugar spikes because glucose from food enters the bloodstream more gradually. While this mechanism is beneficial for both blood sugar control and weight management, it also explains some of the gastrointestinal side effects associated with the medication, including nausea, vomiting, and feelings of excessive fullness.

These effects are most pronounced when starting the medication or increasing the dose.

Blood Sugar Regulation

For individuals with type 2 diabetes, semaglutide's glucose-lowering effects are central to its therapeutic value. The medication stimulates insulin release in a glucose-dependent manner—meaning it only prompts insulin secretion when blood sugar levels are elevated.

This reduces the risk of hypoglycemia compared to some other diabetes medications. Simultaneously, semaglutide suppresses glucagon secretion from the alpha cells of the pancreas.

Glucagon normally signals the liver to release stored glucose, so reducing its secretion helps keep blood sugar levels from climbing too high after meals.

The Cardiovascular and Kidney Connection

The benefits of semaglutide extend well beyond weight loss and blood sugar control. In January 2025, the FDA approved Ozempic (injectable semaglutide) to reduce the risk of worsening kidney disease, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

This approval was based on trial data showing significant renal and cardiovascular protection. The SOUL trial, presented at the American College of Cardiology Annual Scientific Session in March 2025, reinforced these findings for the oral formulation.

The study showed that oral semaglutide reduced major adverse cardiovascular events by 14% in high-risk type 2 diabetes patients. This positions semaglutide as not merely a metabolic medication but a comprehensive cardioprotective agent.

From Injection to Pill The Evolution of Semaglutide Delivery

For years, semaglutide was only available as a subcutaneous injection. Ozempic was approved for type 2 diabetes, and Wegovy—a higher-dose version—was approved for weight management.

The injectable forms remain widely used, but the approval of an oral formulation in December 2025 represents a significant milestone in the medication's evolution.

Why an Oral Formulation Matters

The transition from injection to pill addresses one of the most significant barriers to GLP-1 therapy: needle aversion. Many patients who could benefit from semaglutide are reluctant to start injectable medications.

Others who begin injections may discontinue due to the inconvenience or discomfort of weekly self-administration. The oral tablet eliminates these barriers.

Patients can take the medication at home without any special equipment or training. This accessibility could substantially expand the population that can benefit from the treatment.

However, the oral formulation comes with its own considerations. GLP-1 medications are peptides, which are typically broken down by stomach acid and digestive enzymes before they can be absorbed.

The oral semaglutide tablet uses a special absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to facilitate absorption through the stomach lining. Patients must take the tablet on an empty stomach with a small amount of water and wait at least 30 minutes before eating or drinking anything else.

Approved Doses and Launch Details

The FDA approved oral semaglutide tablets in multiple doses: 1.5 mg, 4 mg, 9 mg, and 25 mg. The starting dose of 1.5 mg is anticipated as the entry point, with gradual dose escalation over time to minimize gastrointestinal side effects.

According to the manufacturer, the oral semaglutide pill is expected to launch in the United States in early January 2026. This timeline means that the medication should be available to patients within weeks of approval.

The approval of the oral formulation also has implications for the broader GLP-1 market. With multiple oral GLP-1 medications in development—including competitors from other pharmaceutical companies—the oral semaglutide approval signals a shift toward more convenient, accessible obesity treatments.

Counterfeit Concerns and Safety Warnings

The popularity of semaglutide has unfortunately attracted counterfeiters. In April 2025, Novo Nordisk issued a warning about counterfeit Ozempic injection 1 mg circulating in the United States.

The FDA has also clarified its policies regarding compounded semaglutide as the national GLP-1 supply begins to stabilize. Patients should only obtain semaglutide from licensed pharmacies with valid prescriptions.

Compounded versions—custom-made copies of the medication—carry additional risks because they are not subject to the same quality controls as FDA-approved products. The FDA may take action regarding compounded products that are substandard quality or otherwise unsafe.

What the Clinical Trials Show Weight Loss Efficacy at Different Doses

The clinical evidence for semaglutide's weight-loss efficacy has accumulated steadily, with each new trial establishing stronger effects at higher doses.

The STEP UP Trial Higher Doses, Greater Results

The STEP UP trial, results of which were presented in January 2025, examined semaglutide 7.2 mg compared to the established 2.4 mg dose and placebo. The findings were striking: the 7.2 mg dose achieved a 20.7% average weight reduction, significantly outperforming both the 2.4 mg dose and placebo.

Even when accounting for treatment adherence—meaning patients who did not take the medication exactly as prescribed—the 7.2 mg dose still achieved 18.7% average weight loss. This suggests that the higher dose provides meaningful additional benefit for patients who need more substantial weight reduction.

The safety and tolerability profile of the 7.2 mg dose was comparable to the lower dose. This is important because it indicates that the higher-dose formulation does not come with proportionally higher side effects, at least in the trial population.

The OASIS 4 Trial Oral Semaglutide at 25 mg

The OASIS 4 trial, published in the New England Journal of Medicine in 2025, examined oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The trial demonstrated that the oral formulation produces clinically meaningful weight loss, establishing the efficacy of the pill form for weight management.

This trial was pivotal in supporting the FDA approval of oral semaglutide for weight management. It showed that the absorption-enhancing technology in the tablet formulation delivers sufficient drug to produce meaningful metabolic effects.

Additional Metabolic Benefits Liver Disease and Blood Sugar

Beyond weight loss, semaglutide has demonstrated benefits in other metabolic conditions. A Phase 3 trial published in the New England Journal of Medicine in April 2025 showed that once-weekly semaglutide at 2.4 mg improved liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced liver fibrosis.

MASH is a serious condition characterized by fat accumulation, inflammation, and liver cell damage. It is strongly associated with obesity and type 2 diabetes.

The finding that semaglutide can improve liver histology—not just reduce weight—suggests that the medication may have direct effects on liver health beyond what would be expected from weight loss alone. The medication also helps normalize blood glucose in patients with prediabetes.

Data presented at ObesityWeek 2025 showed that a higher percentage of participants with prediabetes at baseline achieved normal blood glucose levels at week 64 in the semaglutide group compared to placebo. This is significant because prediabetes is a major risk factor for progression to type 2 diabetes.

Cardiovascular Risk Reduction

The cardiovascular benefits of semaglutide have been consistently demonstrated across trials. The SOUL trial showed a 14% reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients taking oral semaglutide.

This finding was presented at the American College of Cardiology Annual Scientific Session in March 2025 and published in the New England Journal of Medicine. The FDA expanded the Wegovy label in March 2024 to include cardiovascular risk reduction in adults with known heart disease and overweight or obesity.

This means that semaglutide is not just a weight-loss medication—it is also a treatment for cardiovascular risk reduction in appropriate patients.

Who Should Consider Semaglutide and What to Expect

Semaglutide is not a medication for everyone. Understanding who is an appropriate candidate and what the treatment experience entails is essential for making informed decisions.

Candidate Profiles

Semaglutide for weight management is approved for adults with obesity—defined as a body mass index (BMI) of 30 or higher—or adults with overweight (BMI of 27 or higher) who have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. For the diabetes indication, semaglutide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The cardiovascular and kidney disease risk reduction indications apply to adults with type 2 diabetes and established cardiovascular disease, chronic kidney disease, or both.

The Treatment Experience

Patients starting semaglutide should expect a gradual dose escalation schedule. For injectable forms, this typically means starting at a low dose and increasing every four weeks until the maintenance dose is reached.

For the oral formulation, the starting dose of 1.5 mg similarly allows the body to adjust before increasing. Gastrointestinal side effects are common, especially during the titration period.

Nausea, vomiting, diarrhea, and constipation are the most frequently reported issues. These effects typically diminish over time as the body adapts to the medication.

Taking the medication with food (for the injectable form) or following the specific instructions for the oral formulation can help minimize these effects. Weight loss with semaglutide is gradual and progressive.

Clinical trials show that the most significant weight loss occurs over the first six to twelve months of treatment. Patients should not expect immediate results—the medication works cumulatively over time.

Cost and Access Considerations

Semaglutide is a branded medication with significant costs. In August 2025, Novo Nordisk lowered the cost of Ozempic to $499 per month for self-paying patients.

The list price for Wegovy, the weight-management formulation, is higher, though insurance coverage varies widely. Many insurance plans cover semaglutide for type 2 diabetes but may have restrictions for weight management indications.

Prior authorization requirements are common. Patients should check with their insurance providers to understand their coverage and out-of-pocket costs.

The Importance of Lifestyle Modification

Semaglutide is not a replacement for healthy lifestyle habits—it is an adjunct to them. Clinical trials consistently show that the medication is most effective when combined with a reduced-calorie diet and increased physical activity.

The medication makes it easier to adhere to dietary changes by reducing hunger and cravings, but patients still need to make conscious food choices. Long-term weight maintenance is also a consideration.

When patients stop taking semaglutide, they typically regain some of the weight they lost. This means that for many patients, semaglutide is a long-term or even lifelong treatment.

Patients should discuss their long-term treatment plan with their healthcare provider before starting.

Frequently Asked Questions

How does oral semaglutide differ from the injectable version?

The oral tablet uses an absorption enhancer to allow the semaglutide molecule to pass through the stomach lining into the bloodstream. The injectable form delivers the medication directly into subcutaneous tissue.

The oral form must be taken on an empty stomach with minimal water at least 30 minutes before eating. Doses differ between formulations because the oral version has lower bioavailability than the injection.

What is the expected timeline for oral semaglutide availability?

The FDA approved oral semaglutide tablets in December 2025. The manufacturer expects the medication to launch in the United States in early January 2026.

The starting dose of 1.5 mg is anticipated as the entry point for patients beginning treatment.

What are the most common side effects of semaglutide?

Gastrointestinal side effects are most common, including nausea, vomiting, diarrhea, and constipation. These effects are most pronounced when starting the medication or increasing the dose.

Most patients find that these symptoms diminish over time. There are also warnings about counterfeit semaglutide products circulating in the United States, so patients should only use medication from licensed pharmacies with valid prescriptions.

Can semaglutide be used for cardiovascular protection?

Yes. Semaglutide received FDA approval in January 2025 for reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Wegovy also received FDA approval in March 2024 for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. The SOUL trial demonstrated a 14% reduction in major adverse cardiovascular events with oral semaglutide.

Is semaglutide safe for long-term use?

Clinical trials have established safety and tolerability through extended follow-up periods. The medication is approved for chronic use in appropriate patients.

However, patients should work with their healthcare provider to determine the appropriate duration of treatment and to monitor for potential side effects. Weight regain is common after stopping the medication, so long-term treatment plans should be discussed in advance.

Reference Notes

Information in this article is based on publicly available sources. Some details may change over time.

Verify with official sources before acting.